Secondary prevention for coronary artery disease: are we following the guidelines?

被引:3
|
作者
Syed, I. A. A. [1 ]
Riaz, A. [1 ]
Ryan, A. [1 ]
Reilly, M. O. [1 ]
机构
[1] Waterford Reg Hosp, Waterford, Ireland
关键词
Coronary artery disease; Myocardial infarction; Secondary prevention; Statins; Beta-blockers; ACE inhibitors; Aspirin; MYOCARDIAL-INFARCTION;
D O I
10.1007/s11845-010-0527-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Secondary prevention pharmacotherapy in post-myocardial infarction (MI) patients reduces the risk of subsequent coronary events and overall mortality. International guidelines recommend use of aspirin, beta-blockers, ACE inhibitors and statins in post-MI patients. We performed this audit to review the compliance of prescribing practices, in a regional hospital in Ireland, with international guidelines for secondary prevention of coronary artery disease. We performed a retrospective case review of 172 patients diagnosed with MI during a 1-year period between January and December 2007. A total of 134 patients fulfilled the inclusion criteria. On discharge, aspirin was prescribed to 131 (97.76%) patients, clopidogrel to 126 (94%), beta-blockers to 117 (87%), ACE inhibitor to 87 (65%), ARB to 10 (7%) and statins to 116 (87%). Our audit shows that targets for prescription of secondary prevention medications were not met in a small but significant proportion of patients and calls for review of discharge practices and education to improve compliance with guidelines.
引用
收藏
页码:535 / 537
页数:3
相关论文
共 50 条
  • [31] Secondary prevention therapy in patients with coronary artery disease
    Dhond, M
    Amsterdam, EA
    [J]. FORMULARY, 1998, 33 (02) : 120 - +
  • [32] Secondary prevention in patients with known coronary artery disease
    Hunziker, P
    Bertel, O
    [J]. SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1997, 127 (07) : 254 - 260
  • [33] Room for standardisation: the secondary prevention of coronary artery disease
    Bahl, Rahul
    [J]. OPEN HEART, 2021, 8 (02):
  • [34] GUIDELINES FOR PHYSICIANS IN SECONDARY PREVENTION OF CORONARY HEART-DISEASE
    不详
    [J]. KARDIOLOGIYA, 1986, 26 (10) : 109 - 115
  • [35] Secondary prevention patterns in persons with pre-existing coronary artery disease: Are we getting it right?
    Hafidz, Muhammad Imran Abdul
    Zainudin, Lily Diana
    Lee, Zhen-Vin
    Hadi, Mohd Firdaus
    Zuhdi, Ahmad Syadi Mahmood
    [J]. PROCEEDINGS OF SINGAPORE HEALTHCARE, 2018, 27 (03) : 157 - 161
  • [36] The Optimal Antiplatelet Agent for Secondary Prevention of Coronary Artery Disease
    Kumbhani, Dharam J.
    de Lemos, James A.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 82 (02) : 106 - 108
  • [37] Republished: Antiplatelet therapy for secondary prevention of coronary artery disease
    Pilgrim, Thomas
    Windecker, Stephan
    [J]. POSTGRADUATE MEDICAL JOURNAL, 2015, 91 (1075) : 284 - 290
  • [38] Evaluation of a Telemedicine Service for the Secondary Prevention of Coronary Artery Disease
    Blasco, Ana
    Carmona, Montserrat
    Fernandez-Lozano, Ignacio
    Salvador, Carlos H.
    Pascual, Mario
    Sagredo, Pilar G.
    Somolinos, Roberto
    Munoz, Adolfo
    Garcia-Lopez, Fernando
    Escudier, Juan M.
    Mingo, Susana
    Toquero, Jorge
    Monivas, Vanessa
    Gonzalez, Miguel A.
    Fragua, Juan A.
    Lopez-Rodriguez, Fernando
    Monteagudo, Jose L.
    Alonso-Pulpon, Luis
    [J]. JOURNAL OF CARDIOPULMONARY REHABILITATION AND PREVENTION, 2012, 32 (01) : 25 - 31
  • [39] Secondary prevention of coronary artery disease in a cardiology center in Turkey
    Djanmohammedi, A
    Sansoy, V
    Yigit, Z
    Güzelsoy, D
    [J]. ATHEROSCLEROSIS, 1999, 146 : S38 - S38
  • [40] Secondary prevention strategies of coronary artery disease: The possibilities of EPA
    Hirata, Ken-ichi
    [J]. NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2010, 22 : S96 - S96